Status:
UNKNOWN
Telehealth Integrated Care Model in Patients With Cardiometabolic Disease
Lead Sponsor:
Peking University Third Hospital
Conditions:
Cardiometabolic Disease
Hyperlipidemia
Eligibility:
All Genders
16-85 years
Brief Summary
The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicator...
Detailed Description
Efficacy evaluation is critical for understanding the practical application effect of telehealth integrated mode in the therapy of cardiometabolic disease patients. We can comprehend the influence of ...
Eligibility Criteria
Inclusion
- Age ≥ 16 years, and ≤ 85 years;
- Diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus;
- Agreed to be enrolled in this study.
Exclusion
- Undergone percutaneous coronary intervention within one year in our hospital;
- Severe LV dysfunction, such as LV ejection fraction \< 35%, or congestive heart failure with New York Heart Association (NYHA) functional class IV or Killip class IV;
- Structural heart disease, or severe arrhythmia;
- Severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy;
- could not complete at least one-year-followup.
Key Trial Info
Start Date :
June 20 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 20 2025
Estimated Enrollment :
1302 Patients enrolled
Trial Details
Trial ID
NCT06022575
Start Date
June 20 2023
End Date
July 20 2025
Last Update
September 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China